Improving the Adjuvanticity of Small Molecule Immune Potentiators Using Covalently Linked NF-κB Modulators

Area of Science:

• Immunology
• Pharmacology
• Medicinal Chemistry

Background:

• Small molecule immune potentiators (SMIPs), like imidazoquinolinone derivatives, activate Toll-like receptor (TLR) 7/8, showing promise as vaccine adjuvants and antitumor agents.
• High bioavailability of current SMIPs leads to significant systemic inflammation and toxicity, limiting their therapeutic application.
• A need exists for safer immunomodulators with retained or improved efficacy for vaccine and cancer therapy.

Purpose of the Study:

• To design and synthesize novel imidazoquinolinone-based dimers conjugated with NF-κB immunomodulators.
• To evaluate the safety and efficacy of these novel dimers as vaccine adjuvants and antitumor agents.
• To mitigate the systemic toxicity associated with traditional SMIPs.

Main Methods:

• Synthesis of a library of imidazoquinolinone-NF-κB immunomodulator dimers.
• In vitro screening of synthesized dimers to identify viable candidates.
• In vivo vaccination studies in mice using ovalbumin as a model antigen.
• Evaluation of dimer efficacy in a CT26 mouse colon carcinoma tumor model.

Main Results:

• Synthesized dimers demonstrated reduced systemic toxicity compared to conventional SMIPs, bringing it to baseline levels.
• The novel dimers maintained adjuvanticity in vaccine formulations, enhancing immune responses.
• Selected dimers showed improved efficacy in a colon carcinoma tumor model with minimal observed adjuvant toxicity.

Conclusions:

• Novel imidazoquinolinone-NF-κB immunomodulator dimers represent a promising strategy to overcome SMIP-associated toxicity.
• These dimers offer a safer profile for vaccine adjuvants and antitumor therapies.
• Further development of these dimers could lead to more effective and tolerable immunotherapies.